Monday, June 23, 2025 6/23/2025

ENGINEERED HUMAN MICROGLIA AS A CELL-BASED THERAPY FOR A-BETA PLAQUE REMOVAL

Award Number: R21AG073787
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2021
PERIOD OF PERFORMANCE END DATE: 05/31/2024

Group Awards By:

View Award Description

ENGINEERED HUMAN MICROGLIA AS A CELL-BASED THERAPY FOR A-BETA PLAQUE REMOVAL - PROJECT SUMMARY AD is the most common cause of age-related dementia, and is characterized by a progressive impairment in cognitive function. Pathologically, AD patients exhibit Aβ plaques and neurofibrillary tangles with extensive neuronal and synaptic loss. Unfortunately, there is still no effective treatment for this devastating disease. Failures likely arise from amyloid accumulation 10-20 years prior to symptoms and the limited blood brain barrier (BBB) penetrance of many candidate therapies. Earlier diagnoses coupled with an effective and continuous source of in-brain therapy may therefore provide a powerful approach to ameliorate AD pathology. Herein we explore a transformative approach toward delivering therapeutic payloads into the brain to treat Aβ plaque load. We will test if engineered human microglia can be designed to safely and effectively deliver therapies into mouse models of AD. The first specific aim is to demonstrate the feasibility of the approach by determining the change in Aβ load with engineered microglia transplantation. The second aim will determine if reduced Aβ plaque load results in rescue of long-term potentiation defects. Overall, this R21 is poised to test the feasibility of novel and transformative approaches for safe and effective delivery of therapies to combat Aβ plaque buildup on AD. Successful demonstration of this approach could have far-reaching implications for the delivery of therapeutics into the brain.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$6 )
2025	2022	UNIVERSITY OF CALIFORNIA IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Aging Research	000	2	10/15/2024	NON-COMPETING CONTINUATION	-$6
														Subtotal = -$6

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Aging Research	000	2	10/31/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $192,422 )
2022	2022	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Aging Research	000	2	6/24/2022	NON-COMPETING CONTINUATION	$192,422
														Subtotal = $192,422

Issue Date FY: 2021 ( Subtotal = $231,889 )
2021	2021	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Aging Research	000	1	8/25/2021	NEW	$231,889
														Subtotal = $231,889

Grand Total All Awards = $424,305

Top

All Categories

About

Search

Reports

Data Submission

Award Information

ENGINEERED HUMAN MICROGLIA AS A CELL-BASED THERAPY FOR A-BETA PLAQUE REMOVAL

Award Number: R21AG073787

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2021

PERIOD OF PERFORMANCE END DATE: 05/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer